Urothelial carcinoma of the bladder is the most frequent tumor of the urinary tract and
represents the fifth cause of death by cancer worldwide. The current first line chemotherapy …

Abstract The PI3K/AKT/mTOR signaling pathway shows frequent molecular alterations and
increased activity in cancer. Given its role in the regulation of cell growth, survival and …

Loss of TSC1 function, a crucial negative regulator of mTOR signaling, is a common
alteration in bladder cancer. Mutations in other members of the PI3K pathway, leading to …

A complex equilibrium of biological signals exists within the human body to regulate normal
cellular function and growth. Unfortunately, there are various ways in which disruption of …

Advanced bladder cancer is associated with a poor prognosis and limited treatment options.
The PI3K/AKT/mTOR pathway is frequently activated in this disease and can be a potential …

The phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of
rapamycin (mTOR) pathway is a well studied signaling pathway that regulates diverse …

Background The phosphatidyl 3‐inositol kinase (PI3K)/Akt/mechanistic target of rapamycin
(mTOR) pathway frequently is activated in patients with urothelial carcinoma (UC). In the …

Purpose: Activation of the PI3K pathway occurs in over 40% of bladder urothelial cancers.
The aim of this study is to determine the therapeutic potential, the underlying action, and the …

Background Metastatic bladder cancer is a serious condition with a 5-year survival rate of
approximately 14%, a rate that has remained unchanged for almost three decades. Thus …

Objective To examine the ability of dual mTORc1/c2 inhibitors in conjunction with lapatinib to
function in a synergistic manner to inhibit cell proliferation and anchorage-independent …